Noopept (Omberacetam)

1. Overview

Noopept (N-phenylacetyl-L-prolylglycine ethyl ester), also known by the codes GVS-111 and omberacetam, is a synthetic dipeptide nootropic developed at the V.V. Zakusov Research Institute of Pharmacology of the Russian Academy of Medical Sciences in Moscow. It was designed in the mid-1990s by Tatiana Gudasheva and colleagues as a dipeptide analog of the classical nootropic piracetam, based on the hypothesis that piracetam's pyrrolidine ring mimics a proline residue and its N-acetamide moiety mimics glycine [1] [2] [25].

The resulting compound, initially coded GVS-111, demonstrated nootropic effects at doses approximately 1000-fold lower than piracetam (effective at 10-30 mg/day versus 1200-4800 mg/day), with a broader spectrum of cognitive effects encompassing memory acquisition, consolidation, and retrieval, as well as a selective anxiolytic action absent from piracetam [1]. Noopept was patented in 1996, completed Russian Phase III clinical trials, and received regulatory approval in Russia for the treatment of cognitive disorders of cerebrovascular and post-traumatic origin.

Molecularly, noopept has the formula C17H22N2O4 with a molecular weight of 318.37 Da (CAS 157115-85-0). It functions as a prodrug of the endogenous neuropeptide cycloprolylglycine (cyclo-Pro-Gly, cPG), which was identified as the major brain metabolite in 1997 [2]. This endogenous dipeptide is itself a positive modulator of AMPA receptors and exerts neuroprotective effects through AMPA- and TrkB-receptor activation [21] [23].

Noopept is not approved by the FDA, EMA, or other Western regulatory agencies. Outside Russia, it is available as a research compound and as an unregulated supplement in various markets.

Chemical Name

N-phenylacetyl-L-prolylglycine ethyl ester

Molecular Formula

C17H22N2O4

Molecular Weight

318.37 Da

CAS Number

157115-85-0

Active Metabolite

Cycloprolylglycine (cyclo-Pro-Gly)

Routes Studied

Oral, sublingual, intraperitoneal, intravenous

Oral Bioavailability

~10% (parent compound); high CNS penetration confirmed

FDA Status

Not approved; approved in Russia since ~2006 for cognitive disorders

2. Mechanism of Action

Noopept exerts its nootropic and neuroprotective effects through multiple converging molecular mechanisms. Unlike simple receptor agonists, noopept operates as a prodrug that generates an active endogenous neuropeptide, while the parent compound itself also has direct pharmacological activity.

Prodrug Metabolism to Cycloprolylglycine

Following oral administration, noopept is rapidly metabolized in the brain to cycloprolylglycine (cPG), an endogenous cyclic dipeptide consisting of proline and glycine [2]. Gudasheva et al. (1997) first identified cPG as the major brain metabolite of GVS-111, noting its structural identity to a known endogenous neuropeptide [2]. The pharmacokinetics of cPG differ significantly from the parent compound, with a longer plasma residence time suggesting sustained pharmacological activity [22]. Both the parent compound and the metabolite contribute to the overall pharmacological profile.

AMPA and NMDA Receptor Modulation

Cycloprolylglycine was confirmed as an endogenous positive modulator of AMPA receptors [21]. AMPA receptor potentiation enhances fast excitatory glutamatergic neurotransmission and promotes long-term potentiation (LTP), the synaptic mechanism underlying learning and memory. Noopept also modulates NMDA receptor function, contributing to synaptic plasticity. Additionally, noopept at micromolar concentrations reduces both spontaneous and potassium-stimulated glutamate release from cortical slices, suggesting a protective mechanism against glutamate excitotoxicity [8].

BDNF and NGF Upregulation

Ostrovskaya et al. (2008) demonstrated that noopept stimulates expression of nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) mRNA in the rat hippocampus [10]. Acute administration increased both neurotrophins, while chronic 28-day treatment potentiated rather than diminished the effect, demonstrating absence of tolerance [10]. This neurotrophic upregulation is particularly significant because BDNF and NGF are critical for neuronal survival, synaptic plasticity, and long-term memory formation. The streptozotocin Alzheimer model study (2010) further showed that noopept can counteract disease-related decreases in hippocampal NGF and BDNF expression [15].

Cholinergic Enhancement via Alpha-7 Nicotinic Receptors

Noopept modulates cholinergic neurotransmission through multiple mechanisms. Bhatt et al. (2022) demonstrated that noopept (5 micromolar) increased firing frequency of GABAergic interneurons in the CA1 stratum radiatum of rat hippocampal slices [24]. This effect was almost completely abolished by the alpha-7 nicotinic acetylcholine receptor (nAChR) antagonists alpha-bungarotoxin and methyllycaconitine, establishing that alpha-7 nAChRs mediate a key component of noopept's hippocampal activity [24]. In behavioral studies, noopept completely prevented scopolamine-induced spatial memory deficits [9] and protected memory even under combined muscarinic and nicotinic receptor blockade [12].

HIF-1 Pathway Activation

Vakhitova et al. (2016) identified a novel mechanism whereby noopept selectively increases hypoxia-inducible factor 1 (HIF-1) DNA-binding activity by 43% at 10 micromolar, with no significant effects on eight other tested transcription factors including CREB, NF-kB, and p53 [19]. Molecular docking revealed that the pharmacologically active L-isomer of noopept binds to the active site of prolyl hydroxylase 2 (PHD2), a key regulator of HIF-1 degradation. The inactive D-isomer did not show this binding, providing stereochemical evidence for the mechanism [19]. HIF-1 activation promotes expression of genes involved in neuroprotection, angiogenesis, and metabolic adaptation.

Anti-inflammatory and Antioxidant Effects

Noopept demonstrates anti-inflammatory activity through antioxidant mechanisms. Kovalenko et al. (2002) showed that noopept (5 mg/kg IV) suppressed acute carrageenan-induced inflammation by 62.2% and chronic adjuvant arthritis by up to 94.0%, with the anti-inflammatory effect linked to a 5-6 fold suppression of reactive oxygen species production by neutrophilic leukocytes [4]. In the ischemia model, noopept prevented accumulation of lipid peroxidation products and protected antioxidant defense systems [14].

3. Pharmacokinetics

Absorption and Bioavailability

Noopept is absorbed rapidly from the gastrointestinal tract following oral administration, but undergoes extensive first-pass hepatic metabolism that limits oral bioavailability of the parent compound to approximately 10% [3]. Despite this low systemic bioavailability of intact noopept, the compound reaches the central nervous system in unmodified form, as confirmed by Boiko et al. (2000) who detected noopept in rat brain tissue after oral dosing [3]. Sublingual administration bypasses first-pass metabolism by delivering the compound directly into the systemic circulation via the sublingual mucosa, resulting in higher plasma concentrations of the parent compound compared to oral dosing and faster onset of central effects.

Distribution and BBB Penetration

Noopept readily crosses the blood-brain barrier (BBB) in its intact form [3]. After oral administration in rats, Boiko et al. (2000) reported a serum Tmax of approximately 7 minutes (0.116 hours) with a Cmax of 0.82 mcg/mL, indicating extremely rapid absorption and distribution [3]. The rapid BBB penetration is facilitated by noopept's favorable physicochemical properties: a molecular weight of 318.37 Da (well below the ~500 Da cutoff for passive diffusion), moderate lipophilicity, and the absence of a significant charge at physiological pH. Once in the brain, noopept distributes into hippocampal and cortical tissue where it exerts its primary pharmacological effects.

Metabolism and Active Metabolite

Noopept functions as a prodrug. Gudasheva et al. (1997) identified cycloprolylglycine (cyclo-L-prolylglycine, cPG) as the major brain metabolite of GVS-111 [2]. The metabolic pathway involves ester hydrolysis of noopept to produce the free acid (N-phenylacetyl-L-prolylglycine), followed by enzymatic cyclization to cPG and release of phenylacetic acid. cPG is itself an endogenous neuropeptide present in the mammalian brain, establishing noopept as a compound that elevates levels of a naturally occurring signaling molecule [2].

The pharmacokinetic profiles of the parent compound and its active metabolite differ substantially. Zherdev et al. (2018) demonstrated that cPG has a significantly longer plasma residence time than noopept, providing sustained pharmacological activity that extends well beyond the short plasma half-life of the parent compound [22]. This prolonged metabolite activity explains the clinical observation that noopept's cognitive effects persist for hours despite the parent compound's rapid elimination. The parent compound itself has a short plasma half-life, consistent with rapid conversion to active metabolites and distribution into tissues.

First-Pass Metabolism

The extensive first-pass metabolism of oral noopept occurs primarily through hepatic esterases and peptidases. This metabolic susceptibility is characteristic of peptide-based drugs and accounts for the ~10% oral bioavailability [3]. The first-pass effect converts a substantial portion of the oral dose to metabolites before systemic distribution. However, the rapid absorption (Tmax ~7 minutes) ensures that a meaningful fraction of intact noopept reaches the brain before complete metabolism, and the active metabolite cPG generated during first-pass metabolism is itself pharmacologically active and CNS-penetrant.

4. Dose-Response Relationships

Clinical Dose Range and Efficacy

The approved Russian dosing range is 10-30 mg/day, typically administered as 10 mg two to three times daily. Clinical data suggest a relatively flat dose-response curve within this range, with the therapeutic window optimized for cognitive endpoints at 20 mg/day.

10 mg/day: The lowest clinical dose studied. In the Neznamov and Teleshova (2009) trial, 10 mg twice daily (20 mg/day total) produced significant MMSE improvements from 26 to 29 over 56 days [13]. Individual 10 mg doses were sufficient to produce measurable EEG changes including increased alpha- and beta-rhythm power within the first treatment sessions.

20 mg/day: The most commonly studied clinical dose. Both the Neznamov and Teleshova trial (10 mg twice daily) and the Gavrilova and Kolykhalov (2012) post-stroke MCI study (20 mg daily) used this total daily dose [13] [17]. Cognitive improvements were robust across memory, attention, and global function measures. APOE epsilon-4 carriers showed particular benefit at this dose [17].

30 mg/day: The upper end of the approved range (10 mg three times daily). Used in routine clinical practice in Russia but less extensively documented in published controlled trials. The additional 10 mg increment does not appear to produce proportionally greater cognitive benefits in available data, though individual variation in response may justify higher dosing.

The "1000x More Potent Than Piracetam" Claim

The widely cited statement that noopept is 1000 times more potent than piracetam requires careful contextualization. This figure refers strictly to the effective dose comparison: noopept's clinical dose of 10-30 mg/day versus piracetam's 1200-4800 mg/day, yielding an approximately 1000-fold difference in mass administered [1]. This is a potency comparison by dose, not a claim about receptor binding affinity, intrinsic activity, or clinical efficacy magnitude.

The two compounds also differ fundamentally in mechanism. Piracetam acts as a direct allosteric modulator of AMPA receptors with relatively low affinity, requiring high concentrations (and therefore high doses) to achieve receptor occupancy. Noopept, by contrast, is a prodrug that generates the endogenous AMPA modulator cycloprolylglycine, which has higher receptor affinity than piracetam. Furthermore, noopept engages additional pharmacological targets (BDNF/NGF upregulation, alpha-7 nAChR modulation, HIF-1 activation) that piracetam does not. The dose comparison therefore reflects both higher receptor-level potency of the active species and broader mechanism of action, rather than a simple 1000-fold increase in the same pharmacological effect.

EEG Correlates

In the clinical trial by Neznamov and Teleshova (2009), noopept at 20 mg/day produced characteristic nootropic EEG changes: increased alpha-rhythm (8-13 Hz) and beta-rhythm (13-30 Hz) spectral power, with reduced delta-rhythm (0.5-4 Hz) power [13]. Alpha-band enhancement is associated with improved alertness and cognitive processing efficiency, while delta reduction indicates reduced cortical slowing often associated with cognitive impairment. These EEG changes emerged by day 7 of treatment, preceding the full clinical cognitive improvement, and were more pronounced than those observed with piracetam at 1200 mg/day over the same treatment period [13].

5. Comparative Effectiveness

Noopept vs Piracetam

The most direct comparison comes from the Neznamov and Teleshova (2009) clinical trial, which compared noopept (10 mg twice daily) to piracetam (400 mg three times daily) in 53 MCI patients over 56 days [13].

Potency: Noopept achieved comparable or superior cognitive outcomes at approximately 1/60th the daily dose of piracetam (20 mg vs 1200 mg), though the full dose equivalence ratio in animal models is approximately 1:1000 [1].

Onset: Noopept effects emerged by day 7 versus day 14 for piracetam, indicating a faster therapeutic onset [13].

Mechanism: Piracetam acts primarily as a low-affinity allosteric modulator of AMPA receptors. Noopept acts through prodrug conversion to cycloprolylglycine (a higher-affinity endogenous AMPA modulator) plus additional mechanisms including BDNF/NGF upregulation, alpha-7 nAChR activation, and HIF-1 pathway engagement [1] [2] [10] [19] [21] [24].

Spectrum: Piracetam primarily enhances memory acquisition (early-stage encoding). Noopept enhances acquisition, consolidation, and retrieval, providing a broader mnemotropic profile [1]. Noopept also has a selective anxiolytic effect that piracetam lacks [1] [6].

Evidence base: Piracetam has a substantially larger clinical evidence base accumulated over 50+ years, including multiple Western RCTs and Cochrane reviews (which have generally found modest or inconsistent effects). Noopept's clinical evidence is limited to Russian trials with methodological limitations.

Noopept vs Aniracetam

Aniracetam (N-anisoyl-2-pyrrolidone, 750-1500 mg/day) is a lipophilic racetam with AMPA-potentiating and anxiolytic properties. Both noopept and aniracetam positively modulate AMPA receptors and exhibit anxiolytic activity, but through different mechanisms: aniracetam directly binds the AMPA receptor as an allosteric modulator, while noopept generates the endogenous modulator cPG. Noopept is dosed at 50-150 fold lower amounts. Aniracetam has a similarly short half-life (~1-2 hours) and undergoes extensive first-pass metabolism. No head-to-head comparison studies exist. Aniracetam has more Western clinical data (particularly Japanese studies in post-stroke patients), while noopept has stronger preclinical evidence for neurotrophic upregulation.

Noopept vs Pramiracetam

Pramiracetam (600-1200 mg/day) is the most potent classical racetam by dose, though still requiring 20-60 fold higher doses than noopept. Pramiracetam primarily enhances high-affinity choline uptake and has minimal direct glutamatergic activity, contrasting with noopept's AMPA modulation via cPG. Pramiracetam has limited clinical evidence (small studies in head trauma, dementia), comparable in volume to noopept. Neither compound has undergone rigorous Western RCTs for cognitive endpoints. Pramiracetam lacks the neurotrophic (BDNF/NGF) upregulation and anti-inflammatory properties demonstrated for noopept.

Noopept vs Phenylpiracetam

Phenylpiracetam (fonturacetam, 100-300 mg/day) is a phenylated piracetam derivative also developed in Russia. Both compounds are approved in Russia for cognitive disorders. Phenylpiracetam provides more pronounced psychostimulant and physical performance-enhancing effects, leading to its ban by WADA as a stimulant. Noopept lacks stimulant properties and is not banned in sports. Noopept has a stronger neurotrophic and neuroprotective evidence base, while phenylpiracetam has stronger evidence for physical endurance and cold tolerance (originally developed for cosmonauts). The dose comparison is approximately 5-30 fold (phenylpiracetam 100-300 mg vs noopept 10-30 mg).

Noopept vs Semax

Semax (ACTH 4-10 with Pro-Gly-Pro C-terminal extension) is a Russian heptapeptide nootropic administered intranasally at 200-600 mcg/day. Both are Russian-developed peptide nootropics approved for cognitive disorders. Semax is an analog of adrenocorticotropic hormone that stimulates BDNF expression and modulates serotonergic and dopaminergic systems. Key differences: Semax requires intranasal administration (it has no oral bioavailability due to rapid peptide degradation), while noopept is orally active. Both upregulate BDNF, but through different upstream mechanisms. Semax has stronger evidence for acute ischemic stroke treatment (approved for this indication in Russia), while noopept has stronger evidence in chronic cognitive impairment and Alzheimer models. Semax has a more favorable side effect profile in available data, with minimal reports of blood pressure elevation. No direct comparison studies exist.

Noopept vs Modafinil

Modafinil (100-200 mg/day) is an FDA-approved eugeroic (wakefulness-promoting agent) often used off-label as a cognitive enhancer. The compounds target fundamentally different aspects of cognition. Modafinil primarily enhances wakefulness, sustained attention, and executive function through dopaminergic, histaminergic, and orexinergic mechanisms, with no demonstrated effects on memory consolidation or neurotrophic factor expression. Noopept targets memory formation, consolidation, and retrieval through glutamatergic and neurotrophic mechanisms, without wakefulness-promoting effects. Modafinil has a vastly stronger evidence base, including large-scale RCTs and FDA approval for narcolepsy, shift work disorder, and obstructive sleep apnea. Modafinil has a well-characterized side effect profile (headache, nausea, anxiety, insomnia, rare Stevens-Johnson syndrome), schedule IV controlled substance status in the US, and documented (though low) abuse potential. Noopept has no controlled substance classification and no documented dependency potential. The two agents are more complementary than competitive in their pharmacological profiles.

6. Researched Applications

Cognitive Enhancement and Memory

The primary application of noopept is cognitive enhancement. In the foundational review, Ostrovskaya et al. (2002) established that noopept exceeds piracetam in both potency and breadth of mnemotropic activity: while piracetam facilitates only early stages of memory formation, noopept positively influences memory consolidation and retrieval as well [1]. In the BALB/c mouse study, noopept at 0.5 mg/kg completely prevented scopolamine-induced spatial memory deficits in the Morris water maze [9]. Noopept also prevented memory loss under combined muscarinic and nicotinic receptor blockade, suggesting it operates through downstream mechanisms beyond simple cholinergic facilitation [12].

Alzheimer's Disease Models

Noopept has been tested in multiple preclinical models of Alzheimer's disease:

Olfactory bulbectomy model: Noopept at 0.01 mg/kg for 21 days restored spatial memory in bulbectomized mice that develop Alzheimer-like pathology. The drug also increased serum antibodies against amyloid-beta(25-35) oligomers, suggesting an immunomodulatory component to its neuroprotective action [7].

Meynert basal nuclei amyloid injection: Injection of beta-amyloid(25-35) into the nucleus basalis of Meynert caused long-term memory deficits detectable at 24 days. Preventive noopept treatment (0.5 mg/kg for 7 days before injury) completely prevented memory deficits, while therapeutic treatment beginning 15 days after injury significantly improved outcomes despite ongoing neurodegeneration [11].

Streptozotocin sporadic AD model: Intracerebroventricular streptozotocin reduced hippocampal NGF and BDNF expression and increased lipid peroxidation products. Noopept reversed these metabolic changes and improved cognitive function [15].

Amyloid-beta cellular model: Noopept pretreatment of PC12 cells exposed to amyloid-beta(25-35) increased viability from 32% to 230% of control, reduced apoptosis, abolished reactive oxygen species elevation, protected mitochondrial membrane potential, and attenuated tau hyperphosphorylation at Ser396 [18].

Alpha-Synuclein Amyloid Toxicity (Parkinson's Disease Relevance)

Jia et al. (2011) demonstrated that noopept interacted with toxic alpha-synuclein amyloid oligomers through hydrophobic interactions, sequestering them into less cytotoxic larger fibrillar aggregates [16]. This effect rescued cell viability in SH-SY5Y neuroblastoma cells and reduced intracellular oxidative stress, suggesting potential relevance to Parkinson's disease and other synucleinopathies [16].

Cerebral Ischemia

In a chronic cerebral ischemia model using bilateral carotid artery ligation, noopept at 0.5 mg/kg for 7 days post-occlusion reduced neurological deficits, improved survival, normalized exploratory behavior and anxiety measures, and prevented lipid peroxidation product accumulation [14]. The protective effect was observed in rats with both high and low innate sensitivity to hypoxia [14].

Mild Cognitive Impairment in Clinical Settings

In the clinical study by Neznamov and Teleshova (2009), 56-day treatment with noopept (10 mg twice daily) in patients with mild cognitive impairment of cerebrovascular or traumatic origin improved MMSE scores from 26 to 29 [13]. Noopept's effects emerged faster (by day 7) compared to piracetam (day 14), and the drug showed EEG changes characteristic of nootropics: increased alpha- and beta-rhythm power with reduced delta-rhythm power [13]. Gavrilova and Kolykhalov (2012) reported that noopept at 20 mg daily for 2 months improved cognitive functions in stroke patients with MCI, with particular benefit in patients carrying the APOE epsilon-4 allele [17].

Anxiolytic Effects

Noopept produces a selective anxiolytic action not observed with piracetam [1]. This property was traced to its metabolite cycloprolylglycine, which showed anxiolytic activity in the elevated plus-maze test [6]. Gudasheva et al. (2020) further established that cPG's anxiolytic effect is mediated by both AMPA and TrkB (BDNF) receptors [23], providing a mechanistic link between noopept's cognitive enhancement and anxiety reduction. In the ischemia study, noopept normalized elevated plus-maze behavior in brain-injured rats [14].

Glutamate Excitotoxicity Protection

Noopept protects against glutamate-induced neuronal death. Antipova et al. (2016) demonstrated that noopept improved viability of hippocampal HT-22 neurons exposed to toxic glutamate concentrations across a remarkably wide dose range (10^-11 to 10^-5 M), with hippocampal neurons being more sensitive to the protective effect than cortical or cerebellar neurons [20].

7. Clinical Evidence Summary

Clinical evidence for noopept derives from Russian clinical studies. The primary clinical trial by Neznamov and Teleshova (2009) was an open-label comparative study of 53 patients with mild cognitive impairment from vascular or traumatic organic brain disease, comparing noopept (10 mg twice daily) to piracetam (400 mg three times daily) over 56 days [13]. Key outcomes included MMSE improvement from 26 to 29 in the noopept group, faster onset of action (day 7 vs. day 14), and comparable or superior cognitive improvements at a dose approximately 120-fold lower than piracetam.

Gavrilova and Kolykhalov (2012) evaluated noopept at 20 mg daily for 2 months in stroke patients with mild cognitive impairment, reporting improved cognitive function with high safety and suggesting potential for preventing Alzheimer's disease progression, particularly in APOE epsilon-4 carriers [17].

Additional clinical data were referenced in the Phase III trials leading to Russian regulatory approval, though detailed publications of these trials in English-language indexed journals remain limited. The clinical EEG profile of noopept is consistent with established nootropic agents, showing increased alpha- and beta-band power with decreased delta activity.

Limitations of clinical evidence: These trials were conducted in Russian clinical settings, published predominantly in Russian-language journals, and completed without international trial registration. They were generally open-label rather than double-blind randomized controlled trials. Independent replication by non-Russian research groups has not been published. The overall evidence level is classified as moderate primarily due to the extensive preclinical validation and Russian regulatory review, despite the absence of Western clinical trials meeting contemporary standards such as CONSORT reporting.

8. Dosing in Published Research

The following doses have been used in published research. These are not recommendations and should not be interpreted as therapeutic guidance.

The commercially available Russian formulation is typically a 10 mg tablet taken 2-3 times daily (20-30 mg/day total) in courses of 1.5-3 months. Sublingual administration has been used in some contexts due to the compound's relatively low oral bioavailability (~10% for the parent compound), though brain penetration is confirmed regardless of route [3]. In animal studies, intraperitoneal doses of 0.01-0.5 mg/kg have been used, corresponding to the dramatically higher potency compared to piracetam [7] [11] [14].

9. Safety and Side Effects

Preclinical Safety

The comprehensive preclinical toxicity study by Kovalev et al. (2002) evaluated noopept at 10-100 mg/kg orally for 6 months in male and female rabbits [5]. No irreversible pathological changes were found in any organ system. The compound demonstrated no allergenic, immunotoxic, or mutagenic activity, and did not affect reproductive function or prenatal/postnatal progeny development [5]. These doses are 50-500 times the standard human dose on a per-kilogram basis, providing a substantial safety margin. The 6-month duration of this study represents one of the longest chronic toxicity evaluations available for any nootropic compound in the racetam class, covering hepatic, renal, hematological, cardiovascular, and reproductive endpoints.

Clinical Safety Data (Russian Phase III Adverse Events)

In the comparative clinical trial by Neznamov and Teleshova (2009), side effects in the noopept group (n=31) were reported at the following frequencies: elevated blood pressure in 7 patients (22.6%), sleep disturbances in 5 patients (16.1%), and irritability in 3 patients (9.7%) [13]. No serious adverse events requiring treatment discontinuation were reported. All adverse events were classified as mild to moderate in severity. The blood pressure elevation was typically transient and did not require antihypertensive intervention in most cases, though it represents the most clinically significant adverse finding. Sleep disturbances included both insomnia and vivid dreams, generally occurring during the first weeks of treatment and often resolving with continued use or dose adjustment. Gavrilova and Kolykhalov (2012) described the safety profile as favorable at 20 mg daily for 2 months in post-stroke MCI patients [17].

Comparison with Piracetam and Racetams

Noopept differs from piracetam and other racetams in several safety-relevant aspects. Despite being dosed at approximately 1000-fold lower amounts, the therapeutic index appears similar. Noopept is not technically a racetam (it lacks the 2-pyrrolidone ring as a core structure), but is classified as "racetam-like" and shares the pyrrolidine moiety through its proline residue. Unlike some racetams, noopept shows anti-inflammatory activity and does not appear to require choline supplementation.

Contraindications

Based on the Russian prescribing information and available clinical data, the following contraindications apply: known hypersensitivity to noopept or its components; pregnancy and lactation (insufficient safety data); severe hepatic impairment (noopept undergoes extensive hepatic first-pass metabolism, and impaired metabolism could alter exposure levels unpredictably); severe renal impairment (elimination pathway effects unknown); and age under 18 (not studied in pediatric populations). Relative contraindications include uncontrolled hypertension (given the 22.6% incidence of BP elevation in clinical trials [13]) and lactose intolerance (some tablet formulations contain lactose as an excipient).

Dependency and Withdrawal Potential

No dependency, tolerance, or withdrawal syndrome has been documented for noopept in any preclinical or clinical study. The 6-month chronic toxicity study in animals showed no signs of physical dependence [5]. In clinical use at approved doses for 56-day and 2-month courses, no rebound cognitive deterioration or withdrawal symptoms were reported upon discontinuation [13] [17]. The chronic 28-day BDNF/NGF upregulation study demonstrated potentiation rather than tolerance of neurotrophic effects, suggesting absence of pharmacodynamic tolerance to the neurotrophic mechanism [10]. Noopept is not classified as a controlled substance in any jurisdiction. The recommended treatment course structure (1.5-3 months on, followed by a break) is based on the principle of cyclical neuroprotective therapy rather than any evidence of habituation or dependence.

Considerations

Noopept is not regulated as a drug in Western countries and is not available as a prescription medication outside Russia and some former Soviet states. Products sold as noopept in supplement markets are not manufactured under pharmaceutical-grade standards, and purity, identity, and dosing accuracy cannot be guaranteed. Individuals with a history of hypertension should be aware of the blood pressure elevation reported in clinical studies (22.6% incidence at 20 mg/day [13]). Long-term safety data beyond 6-month preclinical studies and 2-month clinical studies are not available. Safety in pregnancy, pediatric populations, and patients with significant hepatic or renal impairment has not been established through dedicated studies. Drug-drug interaction studies have not been formally conducted, though the prodrug metabolism via esterases and peptidases suggests low potential for CYP450-mediated interactions.

10. Related Peptides

See also: Selank, Semax, DSIP

11. References

1. [1] Ostrovskaya RU, Gudasheva TA, Voronina TA, Seredenin SB (2002). The original novel nootropic and neuroprotective agent noopept. Eksp Klin Farmakol. PubMed
2. [2] Gudasheva TA, Boyko SS, Ostrovskaya RU, Voronina TA, Akparov VKh, Trofimov SS, Rozantsev GG, Skoldinov AP, Zherdev VP, Seredenin SB (1997). The major metabolite of dipeptide piracetam analogue GVS-111 in rat brain and its similarity to endogenous neuropeptide cyclo-L-prolylglycine. Eur J Drug Metab Pharmacokinet. PubMed
3. [3] Boiko SS, Ostrovskaya RU, Zherdev VP, Korotkov SA, Gudasheva TA, Voronina TA, Seredenin SB (2000). Pharmacokinetics of new nootropic acylprolyldipeptide and its penetration across the blood-brain barrier after oral administration. Bull Exp Biol Med. PubMed
4. [4] Kovalenko LP, Miramedova AG, Alekseeva SV, Gudasheva TA, Ostrovskaya RU, Seredenin SB (2002). Anti-inflammatory properties of noopept (dipeptide nootropic agent GVS-111). Eksp Klin Farmakol. PubMed
5. [5] Kovalenko LP, Alekseeva SV, Miramedova AG, Gudasheva TA, Ostrovskaya RU, Seredenin SB (2002). Preclinical study of noopept toxicity. Eksp Klin Farmakol. PubMed
6. [6] Gudasheva TA, Konstantinopolsky MA, Ostrovskaya RU, Seredenin SB (2001). Anxiolytic activity of endogenous nootropic dipeptide cycloprolylglycine in elevated plus-maze test. Bull Exp Biol Med. PubMed
7. [7] Ostrovskaya RU, Gruden MA, Bobkova NA, Sewell RDE, Gudasheva TA, Samokhin AN, Seredenin SB, Noppe W, Sherstnev VV, Morozova-Roche LA (2007). The nootropic and neuroprotective proline-containing dipeptide noopept restores spatial memory and increases immunoreactivity to amyloid in an Alzheimer's disease model. J Psychopharmacol. DOI PubMed
8. [8] Us KS, Klodt PM, Kudrin VS, Sapronova AYa, Ostrovskaya RU, Ugryumov MV, Rayevsky KS (2007). The effect of the synthetic neuroprotective dipeptide noopept on glutamate release from rat brain cortex slices. Neurochem J. DOI
9. [9] Belnik AP, Ostrovskaya RU, Gudasheva TA, Voronina TA, Seredenin SB (2007). Dipeptide preparation Noopept prevents scopolamine-induced deficit of spatial memory in BALB/c mice. Bull Exp Biol Med. PubMed
10. [10] Ostrovskaya RU, Gudasheva TA, Zaplina AP, Vahitova JV, Salimgareeva MH, Jamidanov RS, Seredenin SB (2008). Noopept stimulates the expression of NGF and BDNF in rat hippocampus. Bull Exp Biol Med. DOI PubMed
11. [11] Ostrovskaya RU, Belnik AP, Storozheva ZI (2008). Noopept efficiency in experimental Alzheimer disease (cognitive deficiency caused by beta-amyloid(25-35) injection into Meynert basal nuclei of rats). Bull Exp Biol Med. DOI PubMed
12. [12] Ostrovskaya RU, Belnik AP, Storozheva ZI, Seredenin SB (2008). Original nootropic drug noopept prevents memory deficit in rats with muscarinic and nicotinic receptor blockade. Bull Exp Biol Med. PubMed
13. [13] Neznamov GG, Teleshova ES (2009). Comparative studies of noopept and piracetam in the treatment of patients with mild cognitive disorders in organic brain diseases of vascular and traumatic origin. Neurosci Behav Physiol. DOI PubMed
14. [14] Romanova GA, Shakova FM, Barskov IV, Stelmashook EV, Gudasheva TA, Ostrovskaya RU, Seredenin SB (2009). Noopept reduces the postischemic functional and metabolic disorders in the brain of rats with different sensitivity to hypoxia. Bull Exp Biol Med. DOI PubMed
15. [15] Ostrovskaya RU, Vakhitova YV, Salimgareeva MKh, Yamidanov RS, Sadovnikov SV, Zainullina LF, Vakhitov VA, Gudasheva TA, Seredenin SB (2010). Effect of the novel nootropic and neuroprotective dipeptide noopept on the streptozotocin-induced model of sporadic Alzheimer disease in rats. Eksp Klin Farmakol. PubMed
16. [16] Jia X, Gharibyan AL, Ohman A, Liu Y, Olofsson A, Morozova-Roche LA (2011). Neuroprotective and nootropic drug noopept rescues alpha-synuclein amyloid cytotoxicity. J Mol Biol. DOI PubMed
17. [17] Gavrilova SI, Kolykhalov IV (2012). Noopept in the treatment of mild cognitive impairment in patients with stroke. Zh Nevrol Psikhiatr Im S S Korsakova. PubMed
18. [18] Ostrovskaya RU, Vakhitova YV, Kuzmina USh, Salimgareeva MKh, Zainullina LF, Gudasheva TA, Vakhitov VA, Seredenin SB (2014). Neuroprotective effect of novel cognitive enhancer noopept on AD-related cellular model involves the attenuation of apoptosis and tau hyperphosphorylation. J Biomed Sci. DOI PubMed
19. [19] Vakhitova YV, Sadovnikov SV, Borisevich SS, Ostrovskaya RU, Gudasheva TA, Seredenin SB (2016). Molecular mechanism underlying the action of substituted Pro-Gly dipeptide noopept. Acta Naturae. PubMed
20. [20] Antipova TA, Nikolaev SV, Ostrovskaya RU, Gudasheva TA, Seredenin SB (2016). Dipeptide piracetam analogue noopept improves viability of hippocampal HT-22 neurons in the glutamate toxicity model. Bull Exp Biol Med. DOI PubMed
21. [21] Gudasheva TA, Povarnina PYu, Ostrovskaya RU, Seredenin SB (2017). Neuropeptide cycloprolylglycine is an endogenous positive modulator of AMPA receptors. Dokl Biochem Biophys. PubMed
22. [22] Zherdev VP, Boyko SS, Mesonzhnik NV, Appolonova SA (2018). Pharmacokinetics of noopept and its active metabolite cycloprolyl glycine in rats. Eksp Klin Farmakol. PubMed
23. [23] Gudasheva TA, Povarnina PYu, Ostrovskaya RU, Seredenin SB (2020). The anxiolytic effect of the neuropeptide cycloprolylglycine is mediated by AMPA and TrkB receptors. Dokl Biochem Biophys. PubMed
24. [24] Bhatt D, Bhatt S, Bhatt D (2022). Effect of nootropic dipeptide noopept on CA1 pyramidal neurons involves alpha-7 AChRs on interneurons in hippocampal slices from rat. Neurosci Lett. PubMed
25. [25] Gudasheva TA, Ostrovskaya RU, Seredenin SB (2018). Novel technologies for dipeptide drugs design and their implantation. Curr Pharm Des. PubMed